Significant Prevalence of Metabolic Disorders to Drive India Metabolic Disorder Therapeutics Market

Indian metabolic disorder therapeutics market is estimated to grow at a CAGR of 8.5% during the forecast period. As per the National Institutes of Health, in India, the obesity prevalence ranges due to gender, age, and geographical environment. As per the Indian Council of Medical Research–INdia DIABetes study (ICMR-INDIAB) study 2015, in India, the prevalence rate of obesity and central obesity ranges from 11.8% to 31.3% and 16.9% to 36.3% respectively. The treatment of obesity is highly required to lower the risk of having CVD and chronic kidney diseases in the country. Obesity is a kind of metabolic disorder which is characterized by an additional build-up of fat in the body. This leads to an increasing demand for metabolic drugs such as Orlistat (Xenical) and Phentermine. Orlistat (Xenical) works by reducing fat absorption by nearly 30%. It inhibits pancreatic lipases, which results in decreased fat uptake by the gut.

Browse the full report description Indian Metabolic Disorder Therapeutics Market Size, Share & Trends Analysis Report, By Type (Drug Therapy, Gene Therapy, Cellular Transplantation, Enzyme Replacement Therapy, and Others), By Disease (Obesity, Diabetes, Lysosomal Storage Disease, Hypercholesterolemia, and Others) and Forecast, 2020-2026 at https://www.omrglobal.com/industry-reports/indian-metabolic-disorder-therapeutics-market

 Scope of the Indian Metabolic Disorder Therapeutics Market

Market Coverage

• Market number available for 2019-2026
• Base year- 2019
• Forecast period- 2020-2026
• Segment Covered- By Therapy and Disease
• Competitive Landscape- Lupin Ltd., Cipla Inc., AstraZeneca plc, and Biocon Ltd.

Recent Strategic Initiatives in the Indian Metabolic Disorder Therapeutics Market

• In February 2020, AstraZeneca India declared the launch of Qtern (Dapagliflozin 10mg + Saxagliptin 5mg film Coated Tablets) to treat type 2 diabetes. It is shown as an adjunct to exercise and diet for glycemic control improvement in adults suffering from type 2 diabetes mellitus. This oral medication aims to improve blood sugar levels with a significantly low risk of hypoglycemia.
• In November 2019, Lupin declared the launch of the US generic potassium chloride for the oral solution to treat and prevent hypokalemia. This is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is inadequate. 

Key questions addressed by the report

• What is the market growth rate?
• Which segment dominates the market in the base year?
• Which segment will project the fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from the pre-COVID forecast

o Most affected region/segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Indian Metabolic Disorder Therapeutics Market-Segmentation

By Therapy

• Drug Therapy
• Gene Therapy
• Cellular Transplantation
• Enzyme Replacement Therapy
• Others

By Disease

• Obesity
• Diabetes
• Lysosomal Storage Disease
• Hypercholesterolemia
• Others